1. Home
  2. VEON vs NAMS Comparison

VEON vs NAMS Comparison

Compare VEON & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VEON Ltd. ADS

VEON

VEON Ltd. ADS

HOLD

Current Price

$53.11

Market Cap

3.8B

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$32.72

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VEON
NAMS
Founded
1992
2019
Country
United Arab Emirates
Netherlands
Employees
N/A
100
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.5B
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
VEON
NAMS
Price
$53.11
$32.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$73.40
$46.75
AVG Volume (30 Days)
68.3K
761.2K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.21
$17.96
Revenue Next Year
$1.60
$540.65
P/E Ratio
$6.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$34.55
$16.79
52 Week High
$64.00
$42.00

Technical Indicators

Market Signals
Indicator
VEON
NAMS
Relative Strength Index (RSI) 57.33 49.04
Support Level $51.66 $29.73
Resistance Level $56.05 $37.25
Average True Range (ATR) 1.72 1.66
MACD 0.65 -0.02
Stochastic Oscillator 74.51 24.42

Price Performance

Historical Comparison
VEON
NAMS

About VEON VEON Ltd. ADS

VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan. Its telecommunications and digital services include voice, fixed broadband, data and cloud services.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: